Adipotide
Fat LossExperimental fat-vasculature targeting peptideExperimental
Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug.
For research use only.
Key Facts
- CAS
- 859216-15-2
- Molecular Weight (MW)
- —
- Half-life
- —
- Unit
- mg
- Administration Route
- Research parenteral (historical studies)
- Frequency
- —
- Last updated
- 8/23/2026
- Targets
- Prohibitin (adipose vasculature)
Overview
Experimental chimeric peptide designed to induce apoptosis in white-adipose vasculature via prohibitin targeting. Not FDA-approved; development did not yield a drug.
Protocol
- Dosage Range
- Not established for humans
- Frequency
- —
- Cycle
- —
- Administration Route
- Research parenteral (historical studies)
- Reconstitution Guide
- —
Science
Mechanism of Action
Homing motif CKGGRAKDC binds prohibitin on adipose endothelium; a pro-apoptotic KLAKLAK domain then disrupts mitochondrial membranes.
Targets
Prohibitin (adipose vasculature)
Studies
- Adipotide obese primate study— Journal/year not available
Benefits
Historical adipose-vasculature research
Potential Side Effects
- Renal toxicity signal in animals
- No human dose
References
- PMID 21730131External link · Year —
- WADA Prohibited List 2026External link · Year —